BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Adenosine Therapeutics Awarded SBIR Grant To Develop New Compounds For The Treatment Of Parkinson's Disease


10/19/2005 5:12:46 PM

CHARLOTTESVILLE, Va., Feb. 17 /PRNewswire/ -- Adenosine Therapeutics, LLC, a drug discovery and development company, announced today it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Department of Health and Human Services at the National Institute of Health. The grant will fund the development and testing of novel A2A compounds for the treatment of Parkinson's disease. The amount of the award is $139,176.

The goals of the project are to identify and optimize compounds as therapeutic candidates for Parkinson's disease and to evaluate these novel A2A antagonist compounds in the laboratory. This project will be conducted in partnership with Dr. Jiang-Fan Chen at the Boston University School of Medicine.

"We anticipate that this grant will allow us to identify one or more clinical candidates for the treatment of Parkinson's disease. Our goal is to bring one of these new compounds into clinical trials," said Robert S. Capon, CEO and co-founder of Adenosine Therapeutics. "Long term, we are hopeful that this work will lead to more effective treatment for Parkinson's disease, a condition that affects over 1.5 million Americans."

About Adenosine Therapeutics

Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that target adenosine receptor subtypes. Candidates for drug development are identified and screened using the company's state-of- the-art adenosine receptor screening platform technology. The company was founded with the goal of taking new adenosine-receptor selective drugs into clinical trials for a broad range of potential indications. These drug indications include inflammatory indications, sepsis, heart attack, ischemia- reperfusion injury, vascular injury, spinal cord injury, COPD, asthma, diabetes, inflammatory bowel disease, retinopathy, epilepsy, Parkinson's disease, and site-specific angiogenesis. The company's most advanced drug development program is in Phase II clinical development. For more information on Adenosine Therapeutics, visit our web site at http://www.adenrx.com/.

Adenosine Therapeutics, LLC

CONTACT: Robert Capon of Adenosine Therapeutics, LLC, +1-434-220-9400,ext. 201



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES